Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
Greater Sacramento Valley
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD), partial response (PR), or complete response (CR) following completion of standard of care first-line platinum-based induction chemotherapy with pembrolizumab. The primary hypotheses are: participants with confirmed diagnosis of NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus pembrolizumab with respect to Progression-free survival (PFS) and Overall survival (OS).
Principal Investigator
Co-Investigator(s)
Vijay Suhag, M.D., Brian K. Kim, M.D, Jaspreet K Dhillon, Medical Oncologist, Kristie A. Bobolis, M.D., Kristin N. Arreola, M.D., Sivakumar Reddy, M.D., Rajeswari Chellappah, M.D.
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Using EHR from a large healthcare system in Northern CA, we will study the impact of smoking, comorbidities, race on COVID-19 infection and disease severity.
Investigator: Jiang Li, Ph.D., MPH